×

Australia’s Sigma in early talks to acquire British pharmacy Boots

By Thomson Reuters Jun 9, 2026 | 6:48 PM

By Roshan Thomas

June 10 (Reuters) – Australia’s Sigma Healthcare said on Wednesday that it had engaged in preliminary discussions for a potential acquisition of the British pharmacy chain Boots.

The pharmaceutical ​wholesaler and retailer said it continuously reviews opportunities that ‌could create shareholder value, but cautioned there was no certainty any transaction would proceed.

Shares of Sigma Healthcare tumbled more than 5% to hit A$2.76, their lowest closing level since April 28, while the broader Australian benchmark ended 0.7% higher.

“Today’s ‌sell-off ​looks less like a verdict on Boots ⁠and more like a reflection ⁠of investor caution,” said Marc Jocum, a senior product and investment strategist at Global X ETFs.

The company’s statement followed a Financial Times report that said Sigma was among potential bidders for ​Boots in a sale process that could value the British health and beauty retailer at about $10 billion.

A deal would deepen Sigma ⁠Healthcare’s push into the UK market following ⁠its May acquisition of a controlling stake in ​Greenlight Healthcare.

Sigma has also recently completed a merger with Chemist Warehouse, and ​investors are wary that another large acquisition could bring ‌integration, funding, and execution risks, Jocum said.

Private equity firm Sycamore Partners, which took control of Boots last year through the $10 billion acquisition of its parent Walgreens Boots Alliance, entered into discussions with potential strategic ⁠buyers before Easter, the FT reported.

A potential sale would mark a departure from earlier plans to pursue an IPO in London, the FT said.

Reuters ⁠could not independently ‌verify the FT report.

A representative for Boots declined ⁠to comment. Sigma did not immediately respond to ​a Reuters ‌request for comment on the financial details cited ​in the ⁠FT report.

In April, Reuters reported that Boots’ owners were working with consultants on a strategy overhaul ahead of a potential London IPO as soon as 2027, which also included the possibility of a sale.

(Reporting by Roshan Thomas and Roushni Nair in Bengaluru; Editing by Rashmi Aich ​and Mrigank Dhaniwala)